Genetically engineered T cells to target EGFRvIII expressing glioblastoma. Academic Article uri icon

Overview

abstract

  • Glioblastoma remains a significant therapeutic challenge, warranting further investigation of novel therapies. We describe an immunotherapeutic strategy to treat glioblastoma based on adoptive transfer of genetically modified T-lymphocytes (T cells) redirected to kill EGFRvIII expressing gliomas. We constructed a chimeric immune receptor (CIR) specific to EGFRvIII, (MR1-zeta). After in vitro selection and expansion, MR1-zeta genetically modified primary human T-cells specifically recognized EGFRvIII-positive tumor cells as demonstrated by IFN-gamma secretion and efficient tumor lysis compared to control CIRs defective in EGFRvIII binding (MRB-zeta) or signaling (MR1-delzeta). MR1-zeta expressing T cells also inhibited EGFRvIII-positive tumor growth in vivo in a xenografted mouse model. Successful targeting of EGFRvIII-positive tumors via adoptive transfer of genetically modified T cells may represent a new immunotherapy strategy with great potential for clinical applications.

publication date

  • April 23, 2009

Research

keywords

  • ErbB Receptors
  • Glioblastoma
  • T-Lymphocytes

Identity

PubMed Central ID

  • PMC2730985

Scopus Document Identifier

  • 69249248185

Digital Object Identifier (DOI)

  • 10.1016/j.smim.2008.04.001

PubMed ID

  • 19387557

Additional Document Info

volume

  • 94

issue

  • 3